Arcutis Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-2.38	-16.14	-140.04	-262.14	-311.46	-206.36
Depreciation & Amortization	2.25	4.67	1.96	0.75	0.93	0.45
Stock-Based Compensation	41.28	40.36	41.73	38.81	32.68	23.89
Other Adjustments	1.1	0.31	-0.73	-0.98	30.3	3.76
Change in Receivables	-58.96	-73.16	-47.26	-17.35	-8.46	-
Changes in Inventories	-19.96	-7.33	-0.4	-5.62	-7.51	-
Changes in Accounts Payable	3.61	-1.69	2.23	3.15	1.57	0.25
Changes in Accrued Expenses	71.03	50.04	32.03	5.59	1.19	10.46
Changes in Other Operating Activities	-11.07	-2.69	-1.68	-9.28	3.04	-7.09
Operating Cash Flow	26.99	-5.63	-112.16	-247.06	-257.72	-174.63
Capital Expenditures	-0.08	-0.69	-0.14	-0.43	-0.33	-1
Purchases of Intangible Assets	-5	-10	-5	-	-22.95	-
Purchases of Investments	-253.03	-246.99	-254.82	-225.84	-415.39	-292.51
Proceeds from Sale of Investments	209.77	227.42	288.78	406.5	351.47	217.55
Investing Cash Flow	-53.34	-30.25	28.82	180.23	-87.2	-75.95
Long-Term Debt Issued	-	-	-	-	125	73.99
Long-Term Debt Repaid	-	-	-100	-	-	-
Net Long-Term Debt Issued (Repaid)	-	-	-100	-	125	73.99
Issuance of Common Stock	6.99	6.97	166.2	101.32	178.99	209.6
Net Common Stock Issued (Repurchased)	6.99	6.97	166.2	101.32	178.99	209.6
Other Financing Activities	-	-	-	-	-2.19	-1.64
Financing Cash Flow	7.65	6.97	66.2	101.32	301.8	281.95
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.05	0.17	-0.24	-0.05	-	-
Net Cash Flow	-18.65	-28.74	-17.37	34.45	-43.12	31.37
Free Cash Flow	26.92	-6.31	-112.3	-247.49	-258.05	-175.62
FCF Margin	6.48%	-1.68%	-57.14%	-415.20%	-7000.76%	-
Free Cash Flow Per Share	0.21	-0.05	-0.93	-3.57	-4.69	-3.55
Levered Free Cash Flow	43.41	26.17	-206.04	-267.97	-187.57	-129.29
Unlevered Free Cash Flow	51.27	29.13	-95	-249.83	-302.74	-203.45

SEC Filings: 10-K · 10-Q